SEC Form 4 · accession 0001209191-17-030435
Evoke Pharma Inc · EVOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ann D Rhoads
Director
Period of report
May 3, 2017
Accepted (ET)
May 5, 2017 · 6:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001403708
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.72 | May 3, 2017 | A | 36,500 | A | — | May 2, 2027 | Common Stock | 36,500 | 36,500 | D |
Explanation of responses
- F1The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (5/3/2018), subject to the reporting person's continued service to the Issuer through such vesting date.